You are here
The CMLSg will not appeal the NICE FAD which refuses recommendation of dasatinib for first line use in CML.
In the circumstances we feel we have done all we can and that an appeal is not a
positive option for us. We feel our focus must now shift to ensuring that applications to the Cancer Drugs Fund are successful on every occasion a clinician selects that
We feel our focus must now shift to ensuring that applications to the Cancer Drugs Fund are successful on every occasion a clinician selects that
option to access dasatinib for patients in need.
We continue to urge BMS to submit a Patient Access Scheme to the Department of Health.
Please read full statement here: